Inhalation Sciences Sweden AB (publ) (XSAT:ISAB)

Market Cap	9.24M -86.0%
Revenue (ttm)	6.38M -19.6%
Net Income	-9.31M
EPS	-0.27
Shares Out	51.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,702
Open	0.1750
Previous Close	0.1850
Day's Range	0.1750 - 0.1805
52-Week Range	0.1720 - 0.5850
Beta	-0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About XSAT:ISAB

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research in Sweden. The company offers PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exp...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2004
• Employees: 5
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: ISAB

Financial Performance

In 2025, XSAT:ISAB's revenue was 3.04 million, a decrease of -72.47% compared to the previous year's 11.05 million. Losses were -10.16 million, 97.4% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 7, 2026

Data Sources Report a data error